- Home
- PSHG vs BCTX Comparison
PSHG vs BCTX Comparison
Compare PSHG & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSHG
- BCTX
- Stock Information
- Founded
- PSHG 2010
- BCTX 2014
- Country
- PSHG Greece
- BCTX Canada
- Employees
- PSHG N/A
- BCTX N/A
- Industry
- PSHG Marine Transportation
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- PSHG Consumer Discretionary
- BCTX Health Care
- Exchange
- PSHG Nasdaq
- BCTX Nasdaq
- Market Cap
- PSHG 20.1M
- BCTX 17.5M
- IPO Year
- PSHG N/A
- BCTX N/A
- Fundamental
- Price
- PSHG $1.53
- BCTX $3.53
- Analyst Decision
- PSHG Strong Buy
- BCTX Strong Buy
- Analyst Count
- PSHG 1
- BCTX 1
- Target Price
- PSHG $6.50
- BCTX $32.00
- AVG Volume (30 Days)
- PSHG 49.6K
- BCTX 139.2K
- Earning Date
- PSHG 02-20-2025
- BCTX 03-25-2025
- Dividend Yield
- PSHG N/A
- BCTX N/A
- EPS Growth
- PSHG N/A
- BCTX N/A
- EPS
- PSHG 1.11
- BCTX N/A
- Revenue
- PSHG $87,445,000.00
- BCTX N/A
- Revenue This Year
- PSHG N/A
- BCTX N/A
- Revenue Next Year
- PSHG $32.01
- BCTX N/A
- P/E Ratio
- PSHG $1.36
- BCTX N/A
- Revenue Growth
- PSHG N/A
- BCTX N/A
- 52 Week Low
- PSHG $1.48
- BCTX $0.35
- 52 Week High
- PSHG $2.58
- BCTX $7.87
- Technical
- Relative Strength Index (RSI)
- PSHG 44.85
- BCTX 51.61
- Support Level
- PSHG $1.48
- BCTX $3.32
- Resistance Level
- PSHG $1.64
- BCTX $3.71
- Average True Range (ATR)
- PSHG 0.05
- BCTX 0.38
- MACD
- PSHG -0.00
- BCTX -0.13
- Stochastic Oscillator
- PSHG 35.00
- BCTX 36.98
About PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates eight Aframax tanker vessels.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.